Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Hangzhou Gensciences Biopharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New clotting factor aims to stop bleeding in severe hemophilia a Results expected Feb 2027 (estimated)
- New clotting factor aims to cut bleeding episodes in severe hemophilia a Results expected Mar 2027 (estimated)
-
New clotting factor aims to stop bleeding in severe hemophilia a
Disease control OngoingThis phase 3 trial tests a new drug called FRSW107, a lab-made clotting factor VIII fused with a protein that helps it last longer in the body. The study enrolls males aged 12 to 65 with severe hemophilia A who have had at least 150 prior exposure days to factor VIII products. Pa…
Phase 3 • Sponsor: Hangzhou Gensciences Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New clotting factor aims to cut bleeding episodes in severe hemophilia a
Disease control OngoingThis phase 3 trial tests a new drug called FRSW107, a long-lasting version of clotting factor VIII, in people with severe hemophilia A. The study enrolls males aged 12 to 65 who have had at least 150 prior exposure days to factor VIII products. Participants receive regular inject…
Phase 3 • Sponsor: Hangzhou Gensciences Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC